Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regim...
Autors principals: | Döhner, H, Dolnik, A, Tang, L, Seymour, JF, Minden, MD, Stone, RM, Del Castillo, TB, Al-Ali, HK, Santini, V, Vyas, P, Beach, CL, Macbeth, KJ, Skikne, BS, Songer, S, Tu, N, Bullinger, L, Dombret, H |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Springer Nature
2018
|
Ítems similars
-
Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
per: Doehner, H, et al.
Publicat: (2017) -
Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)
per: Doehner, H, et al.
Publicat: (2016) -
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
per: Andrew H. Wei, et al.
Publicat: (2023-03-01) -
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
per: John F. Seymour, et al.
Publicat: (2017-12-01) -
P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
per: A. H. Wei, et al.
Publicat: (2022-06-01)